In discussion with Dr. Daniel G. Stover covering the San Antonio Breast Cancer Symposium 2023 Highlights from Community Oncology perspective.
August 24, 2024
Key Points
APHINITY Sub-analysis: Benefit of Adj Pertuzumab and Trastuzumab According to ER and HER2 Expression
KATHERINE Update: Phase III Study of Adjuvant TDM-1 vs Trastuzumab for Residual Invasive HER2-positive Early Breast Cancer After Neoadj Chemo: Final IDFS and Updated OS analysis
HER2CLIMB-02: Randomized, Double-blind Phase 3 Trial of Tucatinib and TDM1 for Previously Treated HER2-positive Metastatic Breast Cancer
Tags:
Related Posts
ConferencesWCLC2025ArticlesSeptember 18, 2025
WCLC 2025 Highlights: FLAURA2, HARMONi, ALCHEMIST with Dr. Balazs Halmos
ConferencesASCO2025July 31, 2025